Hans-Ulrich Bressel

Learn More
PURPOSE Several studies have suggested a specific association between the presence and/or symptom intensity of benign prostatic hyperplasia (BPH) and diabetes but to our knowledge no definitive conclusion has been reached. Therefore, we examined the intensity of lower urinary tract symptoms in a large cohort of men with BPH with and without diabetes. We(More)
PURPOSE We compare the tolerability and blood pressure effects of 0.4 mg. tamsulosin once daily in patients with lower urinary symptoms suggestive of benign prostatic obstruction with or without concomitant disease and/or antihypertensive medication. MATERIALS AND METHODS Data from 2 open label, observational studies (study 1, 9,507 patients treated for 4(More)
OBJECTIVE To compare the efficacy, global tolerability and blood pressure effects of tamsulosin (0.4 mg once daily) in subgroups of patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO). METHODS Data from two open-label, observational studies (Study I: 9,507 patients treated for 4 weeks, Study II: 9,858(More)
Extracts of whole adult males of Gryllus bimaculatus show distinct maxima of free ecdy­ steroids on the 8th, 12th and 14th day after imaginal moult at a breeding temperature of 25 °C. Isolated OEFC of 11 days old males secrete in vitro free as well as conjugated ecdy­ steroids, although the latter predominate. The bulk of free ecdysteroids seems to consist(More)
AIMS Tamsulosin is an alpha1-adrenoceptor antagonist for the treatment of symptomatic benign prostatic hyperplasia with a tolerability similar to that of placebo in short-term, placebo-controlled studies with limited patient numbers. The present study was designed to test the safety of tamsulosin treatment in a large cohort of men during a prolonged period(More)
  • 1